[Previous Months][Date Index][Thread Index][Join - Register][Login]   Help@Insulin-Pumpers.org
  [Message Prev][Message Next][Thread Prev][Thread Next]   for subscribe/unsubscribe assistance
 
 

[IPu] From: Diabetes In Control ....



                  Special Offers




                  Tools

            Visit our Tools for your Practice Section

                  Special Offers




                  Test Your Knowledge

            View our Test Your Knowledge Section

                  Special Offers



                  Print The Newsletter

            Print This Weeks Newsletter Here

            Newsletter is in Adobe format
            If you don't have Adobe Acrobat Reader, you can download it for
Free here.  Adobe format click here.


                  Special Offers





                        Items for the Week: Lipid-lowering Therapy Prevents
Coronary Events in Diabetics
                        on Tuesday, May 30 @ 10:46:31 CDT

                        Lipid-lowering drug treatment significantly reduced
the risk of major coronary events in patients with and without type 2
diabetes, and that patients with diabetes derived more benefit from
lipid-lowering therapy as primary and secondary prevention.


                        A group of researchers led by Dr Antsnio Vaz Carneiro
of the University of Lisbon School of Medicine, Portugal, evaluated the
effects of lipid-lowering drug treatment in patients with and without
diabetes. A meta-analysis was conducted that included 12 randomized,
double-blind, placebo-controlled trials evaluating lipid-lowering drugs as
primary or secondary prevention of major coronary events in patients with and
without type 2 diabetes. Major coronary events included death due to coronary
heart disease, non-fatal myocardial infarction, or myocardial
revascularization procedures.

                        The researchers found that, in primary prevention,
lipid-lowering therapy reduced the risk of major coronary events similarly in
patients with diabetes (21%, 95% CI 11-30%; p<0.0001) and without diabetes
(23%, 95% CI 12-33%; p=0.0003). In secondary prevention, similar risk
reductions of 21% (95% CI 10-31%; p=0.0005) and 23% (95% CI 19-26%; p=0.00001)
were found. After adjusting for baseline risk, however, patients with diabetes
derived more benefit from lipid-lowering therapy as primary and secondary
prevention than those without diabetes.

                        The researchers concluded that lipid-lowering drug
treatment significantly reduced the risk of major coronary events in patients
with and without type 2 diabetes, and that patients with diabetes derived more
benefit from lipid-lowering therapy as primary and secondary prevention.

                        BMJ 2006;332:1115-24





                        Items for the Week: Lipid-lowering Therapy Prevents
Coronary Events in Diabetics
                        on Tuesday, May 30 @ 10:46:31 CDT

                        Lipid-lowering drug treatment significantly reduced
the risk of major coronary events in patients with and without type 2
diabetes, and that patients with diabetes derived more benefit from
lipid-lowering therapy as primary and secondary prevention.


                        A group of researchers led by Dr Antsnio Vaz Carneiro
of the University of Lisbon School of Medicine, Portugal, evaluated the
effects of lipid-lowering drug treatment in patients with and without
diabetes. A meta-analysis was conducted that included 12 randomized,
double-blind, placebo-controlled trials evaluating lipid-lowering drugs as
primary or secondary prevention of major coronary events in patients with and
without type 2 diabetes. Major coronary events included death due to coronary
heart disease, non-fatal myocardial infarction, or myocardial
revascularization procedures.

                        The researchers found that, in primary prevention,
lipid-lowering therapy reduced the risk of major coronary events similarly in
patients with diabetes (21%, 95% CI 11-30%; p<0.0001) and without diabetes
(23%, 95% CI 12-33%; p=0.0003). In secondary prevention, similar risk
reductions of 21% (95% CI 10-31%; p=0.0005) and 23% (95% CI 19-26%; p=0.00001)
were found. After adjusting for baseline risk, however, patients with diabetes
derived more benefit from lipid-lowering therapy as primary and secondary
prevention than those without diabetes.

                        The researchers concluded that lipid-lowering drug
treatment significantly reduced the risk of major coronary events in patients
with and without type 2 diabetes, and that patients with diabetes derived more
benefit from lipid-lowering therapy as primary and secondary prevention.

                        BMJ 2006;332:1115-24

 [demime 1.01d removed an attachment of type application/octet-stream which had
a name of 14&n=aa2c37b8]

 [demime 1.01d removed an attachment of type application/octet-stream which had
a name of 17&n=a6afe5dc]

 [demime 1.01d removed an attachment of type application/octet-stream which had
a name of 20&n=a623658b]
----------------------------------------------------------
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
help SUPPORT Insulin Pumpers http://www.insulin-pumpers.org/donate.shtml